Chronic kidney disease. Kidney damage with moderately decreased GFR (30-59 mL/min)
Conditions
Interventions
Intervention 1: In the intervention group, the samples receive artichoke capsules ( 320 mg) up to 6 weeks twice daily ( 8 am and 8 pm ). All samples in both intervention and control groups, routinely
Treatment - Drugs
In the intervention group, the samples receive artichoke capsules ( 320 mg) up to 6 weeks twice daily ( 8 am and 8 pm ). All samples in both intervention and control groups, routinely receive atorvas
Sponsors
Vice chancellor for research and technology, Tehran university of medical sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Entry criteria:Patients with chronic kidney disease, stage 3 (GFR: 30-59 mL/min/1.73m2); stage 4 (GFR: 15-29 mL/min/1.73m2); stage 5 (GFR< 15 ml/min/1.73 m 2 ); with failure to control blood lipids (serum LDL =110 mg/dl & cholestrol = 200); without exclusion criteria; also willing to participate in the study; and at least 4 months before the start of the study have received low-fat diet and statin drugs; having a case in considered nephrology center; The willingness of patients to participate in research ??Exclusion criteria: History of biliary obstructive disorders and gallstones; Artichoke use at least one month before the start of the study; unwillingness to continue to cooperate or traveling or death; pregnancy and lactation; the development of side effects of drug; lack of medication over a week.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum LDL concentration. Timepoint: At baseline and at the end of 4 and 8 weeks of study. Method of measurement: Special kits. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum triglyceride concentrations. Timepoint: At baseline and at the end of 4 and 8 weeks of study. Method of measurement: Special kits.;Serum HDL concentrations. Timepoint: At baseline and at the end of 4 and 8 weeks of study. Method of measurement: special kits.;Serum cholestrol concentrations. Timepoint: At baseline and at the end of 4 and 8 weeks of study. Method of measurement: special kits.;Serum CRP concentrations. Timepoint: At baseline and at the end of 4 and 8 weeks of study. Method of measurement: special kits.;Serum ESR concentrations. Timepoint: At baseline and at the end of 4 and 8 weeks of study. Method of measurement: special kits.;Serum ferritin concentrations. Timepoint: At baseline and at the end of 4 and 8 weeks of study. Method of measurement: special kits.;Serum iron concentrations. Timepoint: At baseline and at the end of 4 and 8 weeks of study. Method of measurement: special kits.;Serum TIBC concentrations. Timepoint: At baseline and at the end of 4 and 8 weeks of study. Method of measurement: special kits. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactEbrahim Khadem
School of traditional medicine Tehran university of medical sciences ,Vice chancellor for student in
Outcome results
None listed